Analyst Consensus ?
ConsensusHold22 ratings
Bullish1045.5%
Neutral1150.0%
Bearish14.5%
DaVita Inc. · DVA · FY2024 Q4 · Calendar Q1 2025
DaVita Maintains 2025 Outlook Amid Volume and Supply Constraints
DaVita's growth case rests on reimbursement changes, home dialysis, Integrated Kidney Care, and Latin American expansion, but the evidence is balanced by modest volume growth, supply constraints, and uncertainty around the size and timing of those benefits.
Reported After market closeNYSEHealthcare
$11.95B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $2.14
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $3.27B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-11.1%
Event window
SPY move
-0.0%
Same window
Abnormal move
-11.1%
Stock minus SPY
Volume
8.9×
Versus trailing sessions
Subsequent drift
-5.2%
Up to 20 sessions
DVASPY benchmark
Ask FN2 about DVA FY2024 Q4
Transcript, numbers and history already loaded
What drove DVA's -11.1% move after FY2024 Q4 earnings?What changed in DVA's guidance and outlook in FY2024 Q4?Give me the bull and bear case for DVA after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis adds a $30 million 2025 operating-income headwind from peritoneal-dialysis supply constraints, while emphasizing oral phosphate-binder reimbursement, home dialysis, connected cyclers, Integrated Kidney Care, and Latin American acquisitions as the main areas to monitor.
Guidance delta
Guidance was maintained. The supplied analysis says 2025 targets 5.2% operating-income growth and 11% EPS growth, with a $30 million operating-income headwind from peritoneal-dialysis supply constraints.
Key takeaways
- 2024 adjusted operating income reached $1.98 billion at the lower end of guidance, while EPS reached $9.68.
- Volume growth was modest and below expectations amid supply-chain and hurricane impacts.
- Management highlighted home dialysis, oral phosphate-binder reimbursement, Integrated Kidney Care, and Latin American expansion as growth areas.
Management priorities
- Scale home dialysis and connected-cycler coverage.
- Integrate oral phosphate binders into the dialysis benefit and advance value-based Integrated Kidney Care.
- Complete the remaining Latin American acquisition and maintain disciplined capital spending and share repurchases.
Follow DVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$187.31Current
$81Low
$191.58Average
$270High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 18, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| TD Cowen | Buy | Hold | Upgrade | Aug 7, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Aug 5, 2026 |
| UBS | Buy | Buy | Maintain | Jul 10, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | May 6, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Sep 10, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | May 15, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 23, 2023 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2021 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 6, 2020 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 24, 2020 |
| JP Morgan | Neutral | Neutral | Maintain | Dec 20, 2019 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 7, 2019 |
| Baird | Neutral | Neutral | Maintain | Nov 6, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 11, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 4, 2018 |
| Citigroup | Buy | Neutral | Upgrade | Dec 11, 2017 |
| Jefferies | Hold | Buy | Downgrade | Jun 26, 2017 |
| KeyBanc | Hold | Buy | Downgrade | Sep 17, 2014 |
| Atlantic Equities | Overweight | Overweight | Maintain | Oct 10, 2013 |
| Feltl & Co. | Buy | Buy | Maintain | Oct 31, 2012 |
| Bank oferica | Buy | Buy | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $187.31. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $215 | $179.92 | +14.8% | Aug 7, 2026 |
| Raymond James | Analyst unavailable | $220 | $180.67 | +17.5% | Aug 7, 2026 |
| Oppenheimer | Analyst unavailable | $220 | $180.67 | +17.5% | Aug 7, 2026 |
| Deutsche Bank | Pito Chickering | $265 | $185.52 | +41.5% | Aug 5, 2026 |
| Barclays | Andrew Mok | $224 | $227.99 | +19.6% | Aug 5, 2026 |
| Truist Financial | Analyst unavailable | $250 | $235.58 | +33.5% | Jul 14, 2026 |
| UBS | Analyst unavailable | $270 | $229.48 | +44.1% | Jul 10, 2026 |
| Barclays | Analyst unavailable | $218 | $234.31 | +16.4% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $205 | $194.38 | +9.4% | May 8, 2026 |
| Barclays | Andrew Mok | $194 | $193.88 | +3.6% | May 7, 2026 |
| Deutsche Bank | Pito Chickering | $220 | $157.04 | +17.5% | May 6, 2026 |
| Truist Financial | Analyst unavailable | $158 | $144.42 | -15.6% | Feb 5, 2026 |
| UBS | Analyst unavailable | $190 | $134.73 | +1.4% | Feb 4, 2026 |
| Barclays | Analyst unavailable | $158 | $111.19 | -15.6% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $143 | $126.56 | -23.7% | Oct 30, 2025 |
| Truist Financial | David MacDonald | $140 | $123.36 | -25.3% | Oct 14, 2025 |
| Barclays | Andrew Mok | $149 | $127.89 | -20.5% | Oct 9, 2025 |
| Truist Financial | David MacDonald | $148 | $129.54 | -21.0% | Aug 8, 2025 |
| Bernstein | Lisa Bedell Clive | $184 | $142.4 | -1.8% | Feb 21, 2025 |
| Bank of America Securities | Kevin Fischbeck | $145 | $133.53 | -22.6% | Aug 7, 2024 |
| Barclays | Andrew Mok | $150 | $134.45 | -19.9% | May 6, 2024 |
| Barclays | Sarah James | $81 | $70.54 | -56.8% | Oct 31, 2022 |
| UBS | Andrew Mok | $117 | $93.1 | -37.5% | Aug 19, 2022 |
| Truist Financial | David MacDonald | $90 | $79.44 | -52.0% | Jun 28, 2022 |
Track every rating change on DVA the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationDaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities.…
Historical context
All DVA earningsLatest beats and misses
Who reports nextBeat on EPS
Get the DVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-02-12T14:21:16.591116+00:00
- Polygon adjusted daily market bars · 2026-10-18T10:40:42.640284+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-18T10:40:42.637642+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-18. For educational purposes only; not investment advice.